<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-249X</journal-id>
<journal-title><![CDATA[Journal of the Mexican Chemical Society]]></journal-title>
<abbrev-journal-title><![CDATA[J. Mex. Chem. Soc]]></abbrev-journal-title>
<issn>1870-249X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Química de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-249X2017000400370</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Characterization of Plasma Protein Binding and the Effect of the Vehicle of Docetaxel Formulations]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[Maripaz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quintanar]]></surname>
<given-names><![CDATA[Liliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castañeda-Hernández]]></surname>
<given-names><![CDATA[Gilberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Politécnico Nacional Centro de Investigación y de Estudios Avanzados Departamento de Farmacología]]></institution>
<addr-line><![CDATA[D.F. ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Politécnico Nacional Centro de Investigación y de Estudios Avanzados Departamento de Química]]></institution>
<addr-line><![CDATA[D.F. ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>61</volume>
<numero>4</numero>
<fpage>370</fpage>
<lpage>379</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-249X2017000400370&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-249X2017000400370&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-249X2017000400370&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Resumen. En este estudio proporcionamos evidencia de la unión de la alfa-1- ácido glicoproteína (AAG) a Docetaxel como pieza clave para evaluar las formulaciones de diferentes fabricantes. La comparación de genéricos con el innovador es un campo activo en Farmacéutica. Si bien las pruebas de control de calidad se basan en la evaluación del fármaco activo, nuestros resultados muestran que la unión a proteínas y los excipientes (Polisorbato 80) también juegan un papel crítico. Diseñamos un ensayo por espectroscopia de absorción electrónica para evaluar la unión de Docetaxel a la AAG y la influencia del Polisorbato 80. Evaluamos genéricos de Docetaxel de India y América Latina, nuestros resultados muestran que algunos genéricos de Docetaxel no coinciden con el innovador. El ensayo aquí desarrollado es una técnica factible y de fácil acceso que podría implementarse como una exploración rápida del control de calidad de genéricos de Docetaxel disponibles en todo el mundo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract. In this study we provide evidence of the alpha-1-acid glycoprotein (AAG) binding to Docetaxel as a key assay to evaluate formulations from different manufactures. The comparison of generics to the innovator is an active field in Pharmaceutics. While quality control tests are based on the evaluation of the active drug, our results show protein binding and excipients (Polysorbate 80) also play a critical role. We designed an assay by electronic absorption spectroscopy to evaluate the Docetaxel binding to AAG and the influence of Polysorbate 80. We evaluated Docetaxel generics from India and Latin America, our results show some generics of Docetaxel do not match with the innovator. The assay here developed is a feasible and easy access technique that could be implemented as a quick scan of quality control of Docetaxel generics available worldwide.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Docetaxel]]></kwd>
<kwd lng="en"><![CDATA[alpha-1-acid glycoprotein (AAG)]]></kwd>
<kwd lng="en"><![CDATA[Polysorbate 80]]></kwd>
<kwd lng="en"><![CDATA[generics]]></kwd>
<kwd lng="en"><![CDATA[protein binging]]></kwd>
<kwd lng="es"><![CDATA[Docetaxel]]></kwd>
<kwd lng="es"><![CDATA[alfa-1- ácido glicoproteína (AAG)]]></kwd>
<kwd lng="es"><![CDATA[Polisorbato 80]]></kwd>
<kwd lng="es"><![CDATA[genéricos]]></kwd>
<kwd lng="es"><![CDATA[unión a proteínas]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[S.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[ten Tije]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Figg]]></surname>
<given-names><![CDATA[W.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Graveland]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Verweij]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sparreboom]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Pharmacol Ther.]]></source>
<year>2005</year>
<volume>77</volume>
<page-range>43-53</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vial]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sassiat]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Thiébaut]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Med Res Opin.]]></source>
<year>2008</year>
<volume>24</volume>
<page-range>2019-33</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[S.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Figg]]></surname>
<given-names><![CDATA[W.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Sparreboom]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res.]]></source>
<year>2004</year>
<volume>64</volume>
<page-range>821-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jill]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Oncol Pharm Practice]]></source>
<year>2000</year>
<volume>6</volume>
<page-range>43-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urien]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Barré]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Morin]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Paccaly]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Montay]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Tillement]]></surname>
<given-names><![CDATA[J.P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Invest New Drugs.]]></source>
<year>1996</year>
<volume>14</volume>
<page-range>147-51</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sparreboom]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Brahmer]]></surname>
<given-names><![CDATA[J.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Verweij]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[S.D.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Chromatogr B Analyt Technol Biomed Life Sci.]]></source>
<year>2002</year>
<volume>773</volume>
<page-range>183-90</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carstens]]></surname>
<given-names><![CDATA[M.G.]]></given-names>
</name>
<name>
<surname><![CDATA[de Jong]]></surname>
<given-names><![CDATA[P.H.]]></given-names>
</name>
<name>
<surname><![CDATA[van Nostrum]]></surname>
<given-names><![CDATA[C.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Kemmink]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Verrijk]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[de Leede]]></surname>
<given-names><![CDATA[L.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Crommelin]]></surname>
<given-names><![CDATA[D.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hennink]]></surname>
<given-names><![CDATA[W.E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Pharm Biopharm.]]></source>
<year>2008</year>
<volume>68</volume>
<page-range>596-606</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vasu Dev]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Moses Babu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Vyas]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Sai Ram]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramachandra]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Sekhar]]></surname>
<given-names><![CDATA[N.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mohan Reddy]]></surname>
<given-names><![CDATA[D.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Srinivasa Rao]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Biomed Anal.]]></source>
<year>2006</year>
<volume>40</volume>
<page-range>614-22</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="">
<source><![CDATA[Datamonitor]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<collab>EMEA. Europena Medicines Agency Evaluation of Medicines for Human</collab>
<source><![CDATA[Assessment Report for Docetaxel Teva]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluation of the pharmaceutical quality of docetaxel injection using new stability indicating chromatographic methods for assay and impurities]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malleswara Reddy]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Sci Pharm]]></source>
<year>2010</year>
<volume>78</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>215-31</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loos]]></surname>
<given-names><![CDATA[W.J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Pharmacology &amp; Therapeutics]]></source>
<year>2003</year>
<volume>74</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>364-71</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Morphology of polysorbate 80 (Tween 80) micelles in aqueous 1,4-dioxane solutions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aizawa]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Appl Crystallogr]]></source>
<year>2009</year>
<volume>42</volume>
<page-range>592-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Polysorbate 80 and Cremophor EL micelles deaggregate and solubilize nystatin at the core-corona interface]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Croy]]></surname>
<given-names><![CDATA[S.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[G.S.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Sci]]></source>
<year>2005</year>
<volume>94</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2345-54</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Alternative drug formulations of docetaxel: a review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Engels]]></surname>
<given-names><![CDATA[F.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Mathot]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Verweij]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Anticancer Drugs]]></source>
<year>2007</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>95-103</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Determination of fraction unbound docetaxel using microequilibrium dialysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acharya]]></surname>
<given-names><![CDATA[M.R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Anal Biochem]]></source>
<year>2004</year>
<volume>331</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>192-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman]]></surname>
</name>
<name>
<surname><![CDATA[Gilman]]></surname>
</name>
</person-group>
<source><![CDATA[Las bases farmacológicas de la terapéutica]]></source>
<year>2007</year>
<edition>11</edition>
<publisher-name><![CDATA[M.G. Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ligand binding to a human serum albumin stationary phase: Use of same-drug competition to discriminate pharmacologically relevant interactions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ascoli]]></surname>
<given-names><![CDATA[G.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bertucci]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Salvadori]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biomedical Chromatography]]></source>
<year>1998</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>248-54</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Crystal structure of human serum albumin at 2.5 angstrom resolution]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugio]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Protein Engineering]]></source>
<year>1999</year>
<volume>12</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>439-46</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmaceutically Important Pre- and Posttranslational Modifications on Human Serum Albumin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otagiri]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Chuang]]></surname>
<given-names><![CDATA[V.T.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biological &amp; Pharmaceutical Bulletin]]></source>
<year>2009</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>527-34</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multiple conformational state of human serum albumin around single tryptophan residue at various pH revealed by time-resolved fluorescence spectroscopy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otosu]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimoto]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Yamashita]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biochem]]></source>
<year>2010</year>
<volume>147</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191-200</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A molecular functional study on the interactions of drugs with plasma proteins]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otagiri]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Metab Pharmacokinet]]></source>
<year>2005</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>309-23</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Structural basis of the drug-binding specificity of human serum albumin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghuman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Mol Biol]]></source>
<year>2005</year>
<volume>353</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-52</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schonfeld]]></surname>
<given-names><![CDATA[D.L.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Mol Biol]]></source>
<year>2008</year>
<volume>384</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>393-405</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Isolation and Characterization of Alpha1-Acid Glycoprotein from Rat Serum]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawasaki]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Koyama]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Yamashin]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Biochemistry]]></source>
<year>1966</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>554</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Alpha-1-acid glycoprotein]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fournier]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Medjoubi-N]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Porquet]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochimica Et Biophysica Acta-Protein Structure and Molecular Enzymology]]></source>
<year>2000</year>
<volume>1482</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>157-71</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Plasma-Protein Binding of Basic Drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Routledge]]></surname>
<given-names><![CDATA[P.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[British Journal of Clinical Pharmacology]]></source>
<year>1986</year>
<volume>22</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>499-506</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[alpha(1)-acid glycoprotein reduces local and remote injuries after intestinal ischemia in the rat]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[J.P.]]></given-names>
</name>
</person-group>
<source><![CDATA[American Journal of Physiology-Gastrointestinal and Liver Physiology]]></source>
<year>1997</year>
<volume>273</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>G1031-5</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacological effects of formulation vehicles : implications for cancer chemotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[ten Tije]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2003</year>
<volume>42</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>665-85</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Influence of polysorbate 80 on unbound fractions of anticancer agents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loos]]></surname>
<given-names><![CDATA[W.J.]]></given-names>
</name>
</person-group>
<source><![CDATA[European Journal of Cancer]]></source>
<year>2002</year>
<volume>38</volume>
<page-range>S38</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Interaction of the docetaxel with human serum albumin using optical spectroscopy methods]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[H.X.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Luminescence]]></source>
<year>2009</year>
<volume>129</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1196-203</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Quintanar]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[C.-H.]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Mex Cienc Farm]]></source>
<year>2013</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-51</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
